Vasogen's 2,400-patient ACCLAIM study, which was completed last year.
We are also pleased to announce the other members of the newly formed
ACCLAIM-II steering committee include Guillermo Torre-Amione, MD,
PhD, FACC, Medical Director, Heart Transplant Program, Methodist
DeBakey Heart Center at The Methodist Hospital; Robert Bourge, MD,
Professor & Director of Cardiology Division, Department of Medicine,
University of Alabama at Birmingham; Jean Rouleau, MD, Dean of
Medicine, University of Montreal; Maria Rosa Costanzo, MD, Medical
Director, Edward Center for Heart Failure, Midwest Heart Foundation;
Clyde W. Yancy Jr., MD, Medical Director, Baylor Heart & Vascular
Institute; and Mariell Jessup, MD, Medical Director, Hospital of the
University of Pennsylvania, Heart Failure/Transplant Center.
- A medical symposium focused on the introduction of our
Celacade technology into the European Union was recently held during
the 11th National Conference of Advanced Therapies in Heart Failure
in Spain. The symposium, which was hosted by our European
commercialization partner, Grupo Ferrer Internacional, S.A.
("Ferrer"), was attended by physicians whom Ferrer is targeting to
participate in the initial roll-out of our Celacade technology for
the treatment of heart failure patients. Ferrer is initially
targeting Germany and Spain for the initial commercial launch of
Celacade. Among the presenters at the symposium was Dr. Torre-Amione,
who discussed the importance of the role inflammation plays in the
development and progression of heart failure, and who also reviewed
the results of the ACCLAIM trial of Celacade in chronic heart
failure. The European commercialization activities for Celacade are
|SOURCE Vasogen Inc.|
Copyright©2007 PR Newswire.
All rights reserved